No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Base Pair Mismatch* ; DNA Repair* ; Drug Resistance, Neoplasm* ; Mutation*; Antineoplastic Agents/*pharmacology ; Antineoplastic Agents, Phytogenic/*pharmacology ; Cisplatin/*therapeutic use ; Ovarian Neoplasms/*drug therapy ; Ovarian Neoplasms/*genetics ; Paclitaxel/*therapeutic use ; Tubulin/*biosynthesis ; Tubulin/*genetics; DNA Replication ; Exons ; Female ; Humans ; Microsatellite Repeats/genetics ; Polymerase Chain Reaction ; Sequence Analysis, DNA
    • Abstract:
      Background: The mechanisms of chemoresistance in ovarian cancer patients remain largely to be elucidated. Paclitaxel/cisplatin combination is the standard chemotherapeutic treatment for this disease, although some patients do not respond to therapy. Our goals were to investigate whether TUBB mutations and mismatch repair defects underlie paclitaxel and cisplatin resistance.
      Methods: Thirty-four patients with primary ovarian carcinomas (26 serous and eight clear cell carcinomas) treated with paclitaxel/cisplatin were analysed. TUBB exon 4 was analysed by nested PCR after a first round PCR using intronic primers. Microsatellite analysis was performed with the quasimonomorphic markers BAT 26 and BAT 34.
      Results: Twenty-two of the 34 ovarian cancers (64.7%) presented residual tumour after surgery, seven of which (7/22; 31.8%) were shown to be chemoresistant (five serous and two clear cell tumours). Sequence analysis did not find any mutation in TUBB exon 4. Microsatellite instability was not detected in any of the ovarian carcinomas.
      Conclusion: We conclude that TUBB exon 4 mutations and mismatch repair defects do not play a significant role in paclitaxel/cisplatin resistance.
    • References:
      Int Rev Cytol. 1998;178:207-75. (PMID: 9348671)
      J Biol Chem. 1999 Aug 20;274(34):23875-82. (PMID: 10446152)
      Genes Chromosomes Cancer. 1998 Feb;21(2):101-7. (PMID: 9491320)
      Clin Cancer Res. 1998 Jan;4(1):1-6. (PMID: 9516945)
      Bull Cancer. 1997 Nov;84(11):1061-71. (PMID: 9536988)
      Semin Oncol. 1998 Jun;25(3):340-8. (PMID: 9633846)
      Ann Oncol. 1998 Apr;9(4):423-30. (PMID: 9636834)
      Int J Cancer. 1998 Aug 31;77(5):741-6. (PMID: 9688308)
      J Clin Oncol. 1998 Aug;16(8):2583-90. (PMID: 9704707)
      Gynecol Oncol. 1998 Sep;70(3):398-403. (PMID: 9790794)
      Eur J Cancer. 1998 Sep;34(10):1535-42. (PMID: 9893624)
      Clin Cancer Res. 1997 Oct;3(10):1763-7. (PMID: 9815561)
      Int J Gynecol Pathol. 1999 Apr;18(2):158-62. (PMID: 10202674)
      J Cancer Res Clin Oncol. 1999;125(3-4):156-65. (PMID: 10235469)
      J Clin Oncol. 1999 Jun;17(6):1786-93. (PMID: 10561216)
      Lancet. 2000 Apr 1;355(9210):1176-8. (PMID: 10791395)
      J Natl Cancer Inst. 2000 May 3;92(9):699-708. (PMID: 10793106)
      Cancer. 2000 Jun 1;88(11):2619-28. (PMID: 10861441)
      Int J Gynaecol Obstet. 2000 Aug;70(2):209-62. (PMID: 11041682)
      Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66. (PMID: 11602373)
      J Natl Cancer Inst. 2001 Dec 19;93(24):1886-8. (PMID: 11752014)
      Int J Cancer. 2002 Sep 1;101(1):46-51. (PMID: 12209587)
      Mol Cancer Ther. 2002 Jan;1(3):215-25. (PMID: 12467216)
      Anticancer Res. 2003 Jan-Feb;23(1B):681-6. (PMID: 12680167)
      Nat Rev Cancer. 2003 Jul;3(7):502-16. (PMID: 12835670)
      Gastric Cancer. 2003;6(2):108-12. (PMID: 12861402)
      Cancer Lett. 2003 Jul 30;198(1):89-97. (PMID: 12893435)
      Cancer. 2003 Nov 15;98(10):2199-206. (PMID: 14601090)
      Hum Pathol. 2004 May;35(5):552-9. (PMID: 15138928)
      Int J Cancer. 2004 Nov 20;112(4):643-6. (PMID: 15382045)
      Exp Cell Res. 1986 Apr;163(2):539-48. (PMID: 3007184)
      Mol Cell Biol. 1986 May;6(5):1379-85. (PMID: 2946935)
      Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9495-9. (PMID: 7937795)
      Int J Cancer. 1995 Dec 20;64(6):361-6. (PMID: 8550235)
      Int J Cancer. 1995 Dec 20;64(6):434-40. (PMID: 8550247)
      Cancer Res. 1996 Jul 1;56(13):3087-90. (PMID: 8674066)
      Carcinogenesis. 1996 Sep;17(9):1799-804. (PMID: 8824498)
      Cancer Res. 1996 Nov 1;56(21):4881-6. (PMID: 8895738)
      Cancer Res. 1997 Jan 15;57(2):229-33. (PMID: 9000560)
      Cancer Res. 1997 Jan 15;57(2):300-3. (PMID: 9000572)
      Biochem Pharmacol. 1997 Feb 21;53(4):461-70. (PMID: 9105396)
      Cancer Res. 1997 May 15;57(10):1841-5. (PMID: 9157971)
      J Biol Chem. 1997 Jul 4;272(27):17118-25. (PMID: 9202030)
      J Natl Cancer Inst. 1997 Oct 15;89(20):1537-41. (PMID: 9337351)
      Br J Cancer. 1999 Jun;80(7):1020-5. (PMID: 10362110)
      Br J Cancer. 1998 Feb;77(4):562-6. (PMID: 9484812)
    • Accession Number:
      0 (Antineoplastic Agents)
      0 (Antineoplastic Agents, Phytogenic)
      0 (Tubulin)
      P88XT4IS4D (Paclitaxel)
      Q20Q21Q62J (Cisplatin)
    • Publication Date:
      Date Created: 20050813 Date Completed: 20060227 Latest Revision: 20181113
    • Publication Date:
      20221213
    • Accession Number:
      PMC1199587
    • Accession Number:
      10.1186/1471-2407-5-101
    • Accession Number:
      16095531